AstraZeneca and Pfizer vaccines effective against new COVID-19 Delta Variant shows study.

According to a scientific study, the covid-19 vaccines made by AstraZeneca and Pfizer-BioNTech alliance remain broadly effective against the delta and kappa variants of the covid-19 causing virus which were first identified in India.


Amid the sudden rise of the 'Delta' variant of the novel coronavirus, according to a recent study, it has been discovered that Pfizer-BioNTech's vaccines remain broadly effective against Delta and Kappa variants of the Covid-19 causing virus. Source - NDTV.


"There is no evidence of widespread escape suggesting that the current generation of vaccines will provide protection against the B.1.617 lineage," the paper said, referring to the Delta and Kappa variants by a commonly used code.

But also the concentration for neutralizing the antibodies in the blood was somewhat reduced which may lead to some breakthrough infections, they have cautioned.


An analysis by the Public Health England (PHE), showed that the vaccines which are made by Pfizer Inc and AstraZeneca offer high protection, over 90% against hospitalization from the Delta variant last week.


"We are encouraged to see the non-clinical results published from Oxford and these data, alongside the recent early real-world analysis from Public Health England, provide us with a positive indication that our vaccine can have a significant impact against the Delta variant," AstraZeneca executive Mene Pangalos said in a separate statement.

On Friday, the Chief Scientist of the World Health Organisation has declared the Delta variant as a globally dominant version of the disease.


Also, reinfection patterns in some people have been analyzed who previously had covid-19 by researchers at Oxford. As compared to the individuals who are previously infected by the Beta and Gamma lineages, the risk of infection is high, particularly in the individuals infected by the Delta variant.


Previous infection with the Alpha, or B117, variant first detected in Britain, conferred "reasonable" cross-protection against all variants of concern, lending itself as a template that next-generation vaccines could be molded on.


"B117 might be a candidate for new variant vaccines to provide the broadest protection," the researchers said.

3 views0 comments